Among 2,226 U.S. adults in NHANES 2015–2016, about 26% had discordant apoB and LDL-C. People whose apoB ran high relative to LDL-C were more likely to have elevated hs-CRP (>3 mg/L): 47.6% versus 33.6% in concordant participants. After adjustment for age, sex, BMI and diabetes, odds were 1.58 higher (95% CI 1.03–2.45), rising to 2.02 in non-statin users. The opposite pattern, LDL-C higher than apoB, carried lower odds (OR 0.49).

This fits a growing argument that apoB, which counts atherogenic particles, captures risk that LDL-C misses. Discordantly high apoB usually means many small, cholesterol-poor particles, a profile common in insulin resistance, visceral fat and high triglycerides. That raises an obvious caveat: inflammation may reflect underlying metabolic dysfunction rather than the particles themselves, and adjusting for BMI and diabetes may not fully remove that confounding. The cross-sectional design cannot show direction of cause, hs-CRP was measured once, and the apoB-high subgroup is small, hence the wide confidence intervals. This is a preprint that has not been peer reviewed, so the estimates may shift.

For adults, the practical takeaway is modest but useful: if LDL-C looks acceptable yet triglycerides are high or metabolic health is poor, asking a clinician about an apoB test is reasonable. Overall this is an incremental, confirmatory finding rather than a paradigm shift, and it does not show that lowering apoB reduces inflammation.